중증 근무력증 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Myasthenia Gravis Disease Market size is expected to reach USD 7.80 Billion in 2034 from USD 3.40 Billion (2025) growing at a CAGR of 9.67% during 2026-2034.

The myasthenia gravis market is expanding as advancements in diagnosis, therapeutics, and disease management improve patient outcomes. This autoimmune neuromuscular disorder requires precise treatment strategies involving acetylcholinesterase inhibitors, immunosuppressants, and monoclonal antibodies. Rising prevalence, better disease awareness, and improved access to specialized care are driving global adoption.

Technological innovation is reshaping care. Biologics, targeted therapies, and gene-based interventions enhance symptom management and patient quality of life. AI-assisted diagnostic platforms and wearable neuromuscular monitoring devices enable real-time assessment, treatment optimization, and remote patient management. Integration with digital health ecosystems allows personalized care plans and clinical trial participation.

Future growth is expected from rising patient awareness, research funding, and introduction of novel therapies. North America and Europe dominate adoption due to advanced healthcare infrastructure, while Asia-Pacific is witnessing growing awareness and specialized care centers. Strategic collaborations between biotech firms, pharmaceutical companies, and healthcare providers are accelerating therapeutic innovation. Myasthenia gravis treatment solutions are poised to improve precision care, patient monitoring, and clinical outcomes globally.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Treatment Type

• Cholinesterase Inhibitors
• Chronic Immunomodulators
• Monoclonal Antibodies
• Rapid Immunotherapies
• Thymectomy
• Others

By End-use

• Hospitals
• Clinics
• Others

COMPANIES PROFILED

• Alexion Pharmaceutical Inc, Grifols SA, Avadel Pharmaceuticals plc Novartis AG, Pfizer Inc, AbbVie Inc, F HoffmannLa Roche Ltd, GlaxoSmithKline plc, Bausch Health Companies Inc, Shire plc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MYASTHENIA GRAVIS DISEASE MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Treatment Type
• 4.2. Cholinesterase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Chronic Immunomodulators Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Rapid Immunotherapies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Thymectomy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MYASTHENIA GRAVIS DISEASE MARKET: BY END-USE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End-use
• 5.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MYASTHENIA GRAVIS DISEASE MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Treatment Type
  • 6.2.2 By End-use
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Treatment Type
  • 6.3.2 By End-use
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Treatment Type
  • 6.4.2 By End-use
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Treatment Type
  • 6.5.2 By End-use
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Treatment Type
  • 6.6.2 By End-use
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL MYASTHENIA GRAVIS DISEASE INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Alexion Pharmaceutical Inc
  • 8.2.2 Grifols SA
  • 8.2.3 Avadel Pharmaceuticals Plc. Novartis AG
  • 8.2.4 Pfizer Inc
  • 8.2.5 AbbVie Inc
  • 8.2.6 F. Hoffmann-La Roche Ltd
  • 8.2.7 GlaxoSmithKline Plc
  • 8.2.8 Bausch Health Companies Inc
  • 8.2.9 Shire Plc